Talazoparib is the only once-daily oral PARP inhibitor for the treatment of gBRCA-mutated hormone receptor—positive (HR+)/HER2- or triple-negative locally advanced or metastatic breast cancer.
Talzenna is a pill taken by mouth. The recommended starting dose of Talzenna is a 1-mg tablet taken once per day, with or without food.
Before talazoparib, 3 PARP inhibitors have been approved. They are olaparib, rucaparib and niraparib.Talazoparib is similar to the first inclass PARP inhibitor, olaparib.
Talazoparib sold as brand names Talzenna，It has a generic form of several brands include:
Brand Name : Talacare
Composition : Talazoparib 1mg
Indication: Antineoplastic-PARP inhibitor
Form : Capsule (Oral administration)
Packing : 30 Capsules in 1 box
Manufactured：Elemento Pharm [Laos]
Storage:Store at room temperature (10-30°C)